Philip J. Gold, MD
Seattle, WA 98104
Medical Oncology - Swedish Cancer Institute First Hill
1221 Madison Street, Arnold Pavilion, Suite 200, Seattle, WA 98104
Are you covered?
Check to see if your insurance is covered by this provider.
About Philip J. Gold
Dr. Gold is a multiple time recipient of the Seattle Top Doctor Award and most recently received the 2023 Seattle Magazine Top Doc Award. Dr. Gold is Director of Clinical Research and the Program Leader for the Gastrointestinal (GI) Oncology Program at the Swedish Cancer Institute in Seattle, Washington. In 1991, Dr. Gold obtained his degree in medicine with a distinction in research at the University of Miami School of Medicine in Florida. He then completed an internal medicine internship and residency at the University of Washington. Dr. Gold received the Amgen Oncology Fellowship Award while he was training in medical oncology at the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center.
Presently, he is board certified in medical oncology. Dr. Gold’s clinical investigations on GI tumors, and particularly colorectal cancer treatment, can be found in peer-reviewed publications like the Journal of Clinical Oncology, Seminars in Oncology, and Cancer Investigation. Furthermore, he currently serves as a member of the NCI Colon Task Force, and the Southwest Oncology Group, where he serves as the subcommittee co-chair for colon cancer.
In his free time, Dr. Gold enjoys photography and spending time with his wife and three sons.
University of Washington, WA - Medical Oncology; Fred Hutchinson Cancer Research Center, WA
ResidencyUniversity of Washington School of Medicine
Medical SchoolUniversity of Miami Leonard M. Miller School of Medicine
- American Board of Internal Medicine, Medical Oncology
- Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors
- a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.
- a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
- A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
- Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415).
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
- Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
- Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
- UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
- Phase II trial of paclitaxel, 13-cis retinoic acid and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer
- Long-term survival after continuous infusion interleukin-2.
- Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.
- Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
- Paraneoplastic manifestations of renal cell carcinoma.
- Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
- First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
- Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors
- Pharmacokinetic Analysis of Irinotecan Plus Bevacizumab in Patients with Advanced Solid Tumors
- Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
- A Phase II study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
- Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer
- Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
- Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
- Clinical Trials are Key to new cancer treatments
1221 Madison Street, Suite 200
Seattle, WA 98104
Swedish
Swedish Cherry Hill
Swedish First Hill
Community Reviews
At Swedish, we're dedicated to providing you quality, personalized health care. We are constantly striving to optimize your experience.
As part of ensuring you have a positive experience with Swedish, our online provider directory includes ratings and patient comments for select providers. More about our survey.
I'm pleased with the service provided by the doctors, nurses and clinicians. Thank you.
Swedish Patient
Dr gold is caring, thorough and professional. I appreciate that he is a straight shooter and tells it like it is.
Swedish Patient
Dr Gold always provides up to date care info - and is Always ! Friendly with a great attitude! I' even seen pixs of his dog- when I mentioned I was getting a new puppy. All his staff is equally as great!
Swedish Patient
Dr. Gold is tough and brutally honest but amazing at what he does. His delivery is to be desired, but I feel 100% confident in his care and know he is the best.
Swedish Patient
Dr. Gold and his team are the best group of people I have ever had the pleasure to meet and deal with. I can't say enough about how kind and accommodating they all are.
Swedish Patient
Answers all of my questions, is supportive, takes the time to answer all questions.
Swedish Patient